{"name":"Youngene Therapeutics Inc., Ltd.","slug":"youngene-therapeutics-inc-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxPVEdFQnVwd0NPdlBlZlVUa2p5M0RuRnJlN1l1dHhNMFdicmZoRTZtTWVNeHRZeHJmZnRyanNHT2hQYy1TQWFZT2wzVXdncjF0NWMyNGNYN3hzeVozTGx3aWh4eW9nVGc4RVI0R2o3bE5nVWR3NGlaejNNTkl2dzl3NVRnQ3J1YWFYVXpZYzFrMGgtakdLTUgtUUo5UFNPdE14ZjJwby16VTJoVXlHRDFFVnJuaGJLWUlvOGszbTdFOTZGemhkUjIyaG44bTk2bE5hV001YU9Sa096RWFxRENybTlSX0dVc3VBanVONTl6Y2VqVTMxQ3M0eXByQUxmak5NRV9JZXF5aWkxNlhaYW9tRC01Y0JZcktubGRSdEJlSDEwOUxOQ3RtWkJhOVI0YTM0ZFJxNEx1UHMxV0p4VGRfNGlfNnE?oc=5","date":"2025-09-23","type":"pipeline","source":"PR Newswire","summary":"SGLT2 Inhibitors Market to Expand by 2034 as Companies Leverage Emerging Opportunities in Indications Such as Heart Failure, MASH, Obesity, PCOS, and Others | DelveInsight - PR Newswire","headline":"SGLT2 Inhibitors Market to Expand by 2034 as Companies Leverage Emerging Opportunities in Indications Such as Heart Fail","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPZmNDZGFGdHg1OWhRSXlUN1dyblRieFpYcnJJYlJtUnJsZDBNaGNUbkdyYXVJaHVWTG1sYVlDWGxVbEs5TnY3WGZmZllfZ0EyX1ZyZ2VtNjN6RFhfaU5OSlpkbmdEOTc0RWxldkNmbGE1SnJuY2xqS0doV0VlQndiZUZlX0NqcWhCeVFiVlFRSFBzdw?oc=5","date":"2025-06-18","type":"patent","source":"BioWorld News","summary":"New GLP-1R agonists disclosed in Hengrui patent - BioWorld News","headline":"New GLP-1R agonists disclosed in Hengrui patent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxOY3UwTFY2ZGI5ZXJNUEJVZ3o0ZThCdTFOWm5uN0t4QU0xOUVrOU8ySndNOER3Y2VhVWlDZUJZcWxlc3FpQUFzNERwdTEzdjJyTllyalNuVmwzbEJzX1RUN3hpUDZWZkg0X3VxZmRfYlhhS1M5VDZrLWRxZEJBdFkzSlpFU2NJY2VnRTBGMl9kT2l1aURLbXhLbGtfQXFqWU0wWllEV2RkdkN0TndsbE1iVzZWX1lReXFYZkNTaVJuQUJlXzFQSi1HNjA0Ti1kaVNDcUE4QXBJZU1OUVV3Znk3aHZjdmxMR0pLYjJMUzhPNE51SlcwVGVZcm5DSFl1UGYwb0t2SmJlM0l6TC16TV8ydTNsZlRqanRhbUxsbk9maU82RVpiSmRzeg?oc=5","date":"2025-06-10","type":"trial","source":"GlobeNewswire","summary":"Diabetic Nephropathy Clinical Trial Analysis: Key Insights - GlobeNewswire","headline":"Diabetic Nephropathy Clinical Trial Analysis: Key Insights","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}